Merck/Schering Zetia Effects On Triglycerides, HDL-C Questioned In Review
FDA and Merck/Schering-Plough reached a middle ground on Zetia's indication, allowing the "small" effects on triglycerides and HDL-cholesterol to be described in the clinical studies section of labeling but not in the indication, NDA review documents show
You may also be interested in...
Merck and Schering-Plough are pricing Zetia so that combination use with Zocor 10 mg is attractive compared to high-dose Zocor monotherapy
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials